5-HT1A receptor activation and anti-cataleptic effects: High-efficacy agonists maximally inhibit haloperidol-induced catalepsy

European Journal of Pharmacology

Volumn 453, Issue 2-3, 2002, Pages 217-221

  Prinssen, Eric P M ^a   Colpaert, Francis C ^a   Koek, Wouter ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT1A receptor; Antipsychotic; Catalepsy; Dopamine D2 receptor; Extrapyramidal side effect; Intrinsic activity; Neuroleptic; Schizophrenia

Indexed keywords

2 [4 [4 (7 BENZOFURANYL)PIPERAZINO]BUTYL] 4 METHYL 2H,4H TRIAZIN 3,5 DIONE; 2 [4 [4 (7 METHOXY 1 NAPTHYL) PIPERAZINO]BUTYL] 4 METHYL 2H,4H 1,2,4 TRIAZIN 3,5 DIONE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 CHLORO 4 FLUOROPHENYL [4 FLUORO 4 [[(5 METHYL 6 METHYLAMINOPYRIDIN 2 YLMETHYL)AMINO]METHYL]PIPERIDIN 1 YL METHANONE]FUMARIC ACID SALT; ANTICONVULSIVE AGENT; BUSPIRONE; EPTAPIRONE; F 11461; F 12826; F 13714; HALOPERIDOL; IPSAPIRONE; KETONE DERIVATIVE; LIGAND; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NEUROLEPTIC AGENT; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; SEROTONIN 1 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; MALE; NONHUMAN; POSITION; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; LIGANDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0037174823     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02430-5     Document Type: Article

References (17)

1. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur. J. Pharmacol. 334:1997;141-147.
2. Broekkamp C.L.E., Oosterloo S.K., Berendsen H.H.G., van Delft A.M.L. Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch. Pharmacol. 338:1988;191-195.
3. 1A agonist with exceptional anxiolytic potential. Drug Dev. Res. 26:1992;21-48.
4. 1A receptors. Eur. J. Pharmacol. 401:2000;9-15.
5. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 121:1995;1-26.
6. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48:1991;355-363.
7. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology. 27:1988;515-518.
8. 1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur. J. Pharmacol. 420:2001;103-112.
9. McMillen B.A., Scott S.M., Davanzo E.A. Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J. Pharm. Pharmacol. 40:1988;885-887.
10. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265:1993;207-217.
11. 1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacology. 36:1997;451-459.
12. 1A receptor agonist properties. Eur. J. Pharmacol. 356:1998;189-192.
13. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology. 144:1999;20-29.
14. 1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced. Behav. Pharmacol. 11:2000;299-305.
15. 1A receptors. Eur. J. Pharmacol. 395:2000;143-147.
16. Tallarida R.J., Murray R.B. Manual of Pharmacological Calculations with Computer Programs. 1987;Springer Verlag, New York.
17. Wadenberg M.L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat-enhancement of antipsychotic-like effects without catalepsy. J. Neural. Transm.-Gen. Sect. 83:1991;43-53.